Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutical Product Development (PPD), a global contract research organisation, has appointed Mike Wilkinson, as executive vice president and chief information officer and Paul Colvin as executive vice president of global clinical development effective June 30.
Subscribe to our email newsletter
Dr Wilkinson is expected to provide strategic direction for PPD’s development and deployment of innovative ideas and technology and will oversee the integration of technology initiatives with process improvement, business analytics and global training programs.
Dr Wilkinson has served as executive vice president of global clinical development with responsibility for PPD’s Phase II-IV operations across North America; Latin America; Europe, Middle East and Africa; and Asia Pacific, since last two years.
PPD said that Mr Colvin will assume the role previously held by Dr Wilkinson, providing strategic leadership for global clinical development, including Phase II-IV operations across North America; Latin America; Europe, Middle East and Africa; and Asia Pacific.
Mr Colvin previously served nearly three years as PPD’s senior vice president of clinical development for North America. He joined PPD after 14 years with Eli Lilly in a series of leadership roles that included overseeing clinical operations and global patient enrollment and providing direction for the cardiovascular brand team and oncology, critical care, primary care and neuroscience groups.
David Grange, CEO of PPD, said: “Our efforts are focused on offering our clients a diverse and refined portfolio of services to better address the needs and requirements they face both today and in the future.
“The strategic operational knowledge that Mike Wilkinson brings to the CIO role will add an invaluable dimension in setting the direction for innovative technology and information processing that better supports our core clinical development businesses and ultimately the solutions our customers expect from us.
“Paul Colvin’s extensive experience prior to joining PPD and his significant contributions in leading our North America group make him ideally suited to directing and growing our clinical development operations across six continents. He will provide strong leadership as we continue to adapt and realign to meet the changing drug development needs of our customers.”